Paper41998209
Antitumor immunotoxin expression is enhanced by Escherichia coli csrB-promoter activity.
Hong S and 5 others. Oncogene, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Antitumor immunotoxin expression is enhanced by Escherichia coli csrB-promoter activity. Papers, record 41998209. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41998209
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Escherichia coli | Major topic |
| Promoter Regions, Genetic | Major topic |
| Immunotoxins | Major topic |
| Escherichia coli Proteins | Major topic |
| Animals | |
| Mice | |
| Bacterial Toxins | |
| Exotoxins | |
| Pseudomonas aeruginosa Exotoxin A | |
| Cell Line, Tumor | |
| Humans | |
| Transforming Growth Factor alpha | |
| ADP Ribose Transferases |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| NRF-RS-2023-00210053 | National Research Foundation of Korea (NRF) | NRFRS202300 | PubMed | NIH RePORTER | |
| NRF-RS-2025-02263715 | National Research Foundation of Korea (NRF) | NRFRS202502 | PubMed | NIH RePORTER | |
| 2019M3E5D5066666 | National Research Foundation of Korea (NRF) | PubMed | PubMed | ||
| 2022M3E5F1018375 | National Research Foundation of Korea (NRF) | PubMed | PubMed | ||
| 2025 | Hankuk University of Foreign Studies (HUFS) | PubMed | PubMed |
References57
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23964706 | Tumor-colonizing bacteria: a potential tumor targeting therapy. | Crit Rev Microbiol | 2014 | https://conductscience.org/library/papers/23964706 | PubMed |
| 2 | 40528960 | Engineered bacteria: Strategies and applications in cancer immunotherapy. | Fundam Res | 2025 | https://conductscience.org/library/papers/40528960 | PubMed |
| 3 | 2129426 | Selective killing of tumor cells using EGF or TGF alpha-Pseudomonas exotoxin chimeric molecules. | Semin Cancer Biol | 1990 | https://conductscience.org/library/papers/2129426 | PubMed |
| 4 | 34326488 | Enhancing the tropism of bacteria via genetically programmed biosensors. | Nat Biomed Eng | 2022 | https://conductscience.org/library/papers/34326488 | PubMed |
| 5 | 37509078 | Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment. | Biomolecules | 2023 | https://conductscience.org/library/papers/37509078 | PubMed |
| 6 | 8313355 | Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. | Cancer Res | 1994 | https://conductscience.org/library/papers/8313355 | PubMed |
| 7 | 39502977 | Microbial Therapeutics in Oncology: A Comprehensive Review of Bacterial Role in Cancer Treatment. | Cureus | 2024 | https://conductscience.org/library/papers/39502977 | PubMed |
| 8 | 28286304 | Regulation of hypoxia-inducible gene expression after HIF activation. | Exp Cell Res | 2017 | https://conductscience.org/library/papers/28286304 | PubMed |
| 9 | 30278129 | Modular Pore-Forming Immunotoxins with Caged Cytotoxicity Tailored by Directed Evolution. | ACS Chem Biol | 2018 | https://conductscience.org/library/papers/30278129 | PubMed |
| 10 | 8339264 | Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. | Cancer Res | 1993 | https://conductscience.org/library/papers/8339264 | PubMed |
| 11 | 38053546 | Bacterial cancer therapy using the attenuated fowl-adapted Salmonella enterica serovar Gallinarum. | Mol Ther Oncolytics | 2023 | https://conductscience.org/library/papers/38053546 | PubMed |
| 12 | 37201582 | Spatiotemporal regulation of the BarA/UvrY two-component signaling system. | J Biol Chem | 2023 | https://conductscience.org/library/papers/37201582 | PubMed |
| 13 | 37906273 | Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | https://conductscience.org/library/papers/37906273 | PubMed |
| 14 | 36900277 | Constitutive Expression of a Cytotoxic Anticancer Protein in Tumor-Colonizing Bacteria. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36900277 | PubMed |
| 15 | 36123348 | Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. | Signal Transduct Target Ther | 2022 | https://conductscience.org/library/papers/36123348 | PubMed |
| 16 | 20436464 | Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. | Nat Biotechnol | 2010 | https://conductscience.org/library/papers/20436464 | PubMed |
| 17 | 35151278 | The impact of the human microbiome in tumorigenesis, cancer progression, and biotherapeutic development. | BMC Microbiol | 2022 | https://conductscience.org/library/papers/35151278 | PubMed |
| 18 | 31160120 | Acetate Metabolism in Physiology, Cancer, and Beyond. | Trends Cell Biol | 2019 | https://conductscience.org/library/papers/31160120 | PubMed |
| 19 | 35681100 | Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors. | Nat Cancer | 2022 | https://conductscience.org/library/papers/35681100 | PubMed |
| 20 | 25853312 | Potent and tumor specific: arming bacteria with therapeutic proteins. | Ther Deliv | 2015 | https://conductscience.org/library/papers/25853312 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42415153 | From tumor targeting to tumor accessibility: surface-engineered bacteria as precision living therapeutics for translational medicine. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42415153 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41998209
GET https://conductscience.org/api/papers/v1/41998209/references?page=2